Treatment of Edoxaban Versus Aspirin for Non-disabling Cerebrovascular Events: Rationale, Objectives, and Design

Trial Profile

Treatment of Edoxaban Versus Aspirin for Non-disabling Cerebrovascular Events: Rationale, Objectives, and Design

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Edoxaban (Primary) ; Aspirin
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms Xijing-Edoxaban
  • Most Recent Events

    • 22 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top